ArticleTransplant international : official journal of the European Society for Organ Transplantation2025
Economic Burden and Healthcare Trajectories of Patients Awaiting Heart Transplantation in a French Tertiary Center.
Article in Transplant international : official journal of the European Society for Organ Transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Long-term outcomes of patients implanted with a HeartMate 3 left ventricular assist device-a real-world, single-centre, observational study.ESC heart failure · 2026Observational
- Modeling the cost-effectiveness of introducing donation after controlled circulatory death for heart transplantation in France.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart transplantation (HT) is the gold standard treatment of end-stage heart failure, but organ shortage remains a challenge. This retrospective cohort study assesses the economic burden and healthcare pathways of patients awaiting HT in a French tertiary center. Direct healthcare resources were collected and valued, and a state sequence analysis was performed. Ninety-two adult patients were included, with 67 (73%) undergoing HT within a median waiting time of 2 months. The mean cost per patient was €21,324.05 with an average of 2.71 hospitalizations. Four clusters were identified. Type 1 patients (n = 43) underwent HT within 1 month, with a mean cost of €5,820.12 per patient. Only 4 (25%) Type 2 patients (n = 16) underwent HT within 30 months, as they were not prioritized for HT, with a mean cost of €22,285.32 per patient. Type 3 patients (n = 20) underwent HT within 10 months, but incurred higher costs (€27,541.11) compared to Type 2 patients over a shorter period. Despite high transplant priority, Type 4 patients (n = 13) died before HT within 3 months, with a mean cost of €61,858.45 and 3 hospitalizations. This work highlights the economic burden of organ shortage. The use of novel heart preservation devices (such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.